Scarica l'app Stockscreener
80.04
5.57%
4.22
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DXCM Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$75.82
Aprire:
$75.47
Volume 24 ore:
10.40M
Relative Volume:
2.56
Capitalizzazione di mercato:
$31.26B
Reddito:
$3.95B
Utile/perdita netta:
$680.80M
Rapporto P/E:
87.96
EPS:
0.91
Flusso di cassa netto:
$535.00M
1 W Prestazione:
+3.69%
1M Prestazione:
+6.38%
6M Prestazione:
-31.04%
1 anno Prestazione:
-31.38%
Intervallo 1D:
$75.47
$81.51
Intervallo di 1 settimana:
$74.50
$81.51
Portata 52W:
$62.34
$142.00
Dexcom Inc Stock (DXCM) Company Profile
Nome
Dexcom Inc
Settore
Industria
Telefono
(858) 200-0200
Indirizzo
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Confronta DXCM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
80.04 | 31.26B | 3.95B | 680.80M | 535.00M | 1.67 |
|
ABT
Abbott Laboratories
|
114.23 | 198.13B | 41.22B | 5.77B | 6.49B | 3.29 |
|
SYK
Stryker Corp
|
364.60 | 138.99B | 21.97B | 3.59B | 3.21B | 9.33 |
|
BSX
Boston Scientific Corp
|
88.95 | 131.10B | 15.91B | 1.79B | 1.89B | 1.21 |
|
MDT
Medtronic Plc
|
81.03 | 103.90B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
74.81 | 44.12B | 6.60B | 4.16B | 490.10M | 6.93 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-07-26 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | Iniziato | Redburn Atlantic | Neutral |
| 2024-03-12 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-05-30 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-04-17 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2023-01-26 | Iniziato | Wolfe Research | Outperform |
| 2022-10-18 | Iniziato | Barclays | Equal Weight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-07-15 | Iniziato | Bernstein | Outperform |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-02-03 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2022-01-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-10-18 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-07-21 | Ripresa | Cowen | Outperform |
| 2021-05-28 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Overweight |
| 2021-01-06 | Aggiornamento | UBS | Neutral → Buy |
| 2020-10-02 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | Reiterato | Piper Sandler | Overweight |
| 2020-05-14 | Iniziato | Wells Fargo | Equal Weight |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-11-07 | Reiterato | Canaccord Genuity | Buy |
| 2019-11-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-10-23 | Iniziato | Stifel | Buy |
| 2018-11-28 | Iniziato | UBS | Neutral |
| 2018-10-19 | Aggiornamento | Goldman | Sell → Neutral |
| 2018-09-12 | Aggiornamento | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | Reiterato | Canaccord Genuity | Buy |
| 2018-07-02 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-05-11 | Iniziato | BofA/Merrill | Buy |
| 2018-05-03 | Reiterato | Canaccord Genuity | Buy |
| 2018-04-04 | Iniziato | Goldman | Sell |
| 2018-04-04 | Iniziato | Guggenheim | Neutral |
| 2018-03-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | Downgrade | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | Reiterato | Wedbush | Outperform |
Mostra tutto
Dexcom Inc Borsa (DXCM) Ultime notizie
1 Reason to Sell DexCom Stock, and 1 Reason to Buy - Yahoo Finance
DexCom (NASDAQ:DXCM) Trading 7.3% HigherStill a Buy? - MarketBeat
Orion Portfolio Solutions LLC Cuts Stake in DexCom, Inc. (NASDAQ:DXCM) - MarketBeat
Ōura closes $200M series D, Dexcom invests $75M - BioWorld Online
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
TNDM Stock to Gain From t:slim X2 With Dexcom G7 Launch in Canada - MSN
Oura boosts valuation to $5.2B in latest funding round (NASDAQ:DXCM) - Seeking Alpha
Diabetes Brands Dexcom, Ozempic, Mounjaro Drive Q3 Convergent TV Ad Engagement - Business Wire
UPC latest: CoA decision has retroactive effect | Dexcom defeat | 2025 predictions - Managing Intellectual Property
DexCom, Inc. Class Action: Levi & Korsinsky Reminds DexCom Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 21, 2024DXCM - The Eastern Progress Online
DexCom Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Dexcom implements GenAI into glucose biosensor devices - Yahoo Finance
Dexcom adds generative AI to over-the-counter CGMs - MedTech Dive
Insiders At DexCom Sold US$18m In Stock, Alluding To Potential Weakness - Simply Wall St
AI-Driven Glucose Biosensing: Dexcom’s (DXCM) Path To A Comeback - Yahoo Finance
Dexcom director Bridgette Heller sells shares for $76,870 By Investing.com - Investing.com Australia
Dexcom's COO Jacob Leach sells $57,191 in stock By Investing.com - Investing.com South Africa
Dexcom director Bridgette Heller sells shares for $76,870 - Investing.com India
Dexcom's COO Jacob Leach sells $57,191 in stock - Investing.com
Dexcom launches generative AI platform for glucose biosensing - Mass Device
Dexcom Rolls Out GenAI Platform for Stelo CGM - MPO-mag
Dexcom Launches First-Ever GenAI Platform for Glucose Monitoring, Partners with Google Cloud - StockTitan
Dexcom G7 CGM System Now Covered by Alberta Government for Type 1 & 2 Diabetes Patients - StockTitan
Is Dexcom, Inc. (DXCM) the Best Weight Loss Stock to Buy Now According to Hedge Funds? - Insider Monkey
Dexcom shares up as Diabetes Association updates guidelines - MSN
Lord Abbett & CO. LLC Sells 23,004,568 Shares of DexCom, Inc. (NASDAQ:DXCM) - MarketBeat
MML Investors Services LLC Reduces Stock Position in DexCom, Inc. (NASDAQ:DXCM) - MarketBeat
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now - MSN
DexCom, Inc. (NASDAQ:DXCM) Short Interest Update - MarketBeat
DexCom's SWOT analysis: cgm maker faces challenges amid stock volatility - Investing.com
Tidal Investments LLC Raises Stock Holdings in DexCom, Inc. (NASDAQ:DXCM) - MarketBeat
World Investment Advisors LLC Purchases Shares of 35,066 DexCom, Inc. (NASDAQ:DXCM) - MarketBeat
Virtu Financial LLC Buys New Shares in DexCom, Inc. (NASDAQ:DXCM) - MarketBeat
M&T Bank Corp Decreases Stake in DexCom, Inc. (NASDAQ:DXCM) - MarketBeat
Stifel Financial Corp Sells 24,859 Shares of DexCom, Inc. (NASDAQ:DXCM) - MarketBeat
Brokerages Set DexCom, Inc. (NASDAQ:DXCM) Target Price at $98.00 - MarketBeat
DexCom (NASDAQ:DXCM) Price Target Raised to $94.00 - Defense World
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of DexCom - The Eastern Progress Online
DexCom Stock Price | DXCM Stock Quote, News, and History - Markets Insider
DexCom, Inc. (NASDAQ:DXCM) Shares Bought by Geode Capital Management LLC - MarketBeat
DXCM Deadline in 4 Days: Kessler Topaz Meltzer & Check, LLP Reminds DexCom, Inc. (DXCM) Investors of Filing Deadline in Class Action Lawsuit - The Eastern Progress Online
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against DexCom, Inc.DXCM - The Eastern Progress Online
Continuous Glucose Monitoring Devices Market Set to Witness Significant Growth by 2024-2031: Dexcom, Inc., - EIN News
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit - The Eastern Progress Online
DexCom Inc. stock underperforms Thursday when compared to competitors - MarketWatch
The Gross Law Firm Notifies DexCom, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineDXCM - Kilgore News Herald
European court rules in favor of Abbott in Dexcom CGM patent spat - Mass Device
Public Employees Retirement System of Ohio Has $9.78 Million Position in DexCom, Inc. (NASDAQ:DXCM) - MarketBeat
Quantinno Capital Management LP Decreases Position in DexCom, Inc. (NASDAQ:DXCM) - MarketBeat
Faruqi & Faruqi Reminds DexCom Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 21, 2024DXCM - The Eastern Progress Online
Abbott Gets Another Dexcom Patent Revoked At UPC - Law360
Dexcom Inc Azioni (DXCM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Dexcom Inc Azioni (DXCM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Sylvain Jereme M | EVP, Chief Financal Officer |
Dec 16 '24 |
Sale |
76.87 |
744 |
57,191 |
80,030 |
| Leach Jacob Steven | EVP, Chief Operating Officer |
Dec 16 '24 |
Sale |
76.87 |
744 |
57,191 |
264,171 |
| Heller Bridgette P | Director |
Dec 16 '24 |
Sale |
76.87 |
1,000 |
76,870 |
23,349 |
1.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):